Avista Pharma Solutions to Manufacture Small Molecule to Treat Opioid Addiction
PTSM: Pharmaceutical Technology Sourcing and Management
The Minneapolis Medical Research Foundation has contracted Avista to manufacture an opioid-derived small molecule as a component for a vaccine to treat opioid addiction.
The Minneapolis Medical Research Foundation (MMRF), a nonprofit subsidiary of the Hennepin Healthcare System, Inc. in Minneapolis, has contracted Avista Pharma Solutions to manufacture an opioid-derived small molecule, a key component of a conjugate vaccine in development to treat opioid addiction. In a May 15, 2017 press release, the company said the research is funded by a three-year grant to the MMRF from the National Institute on Drug Abuse.
Avista Pharma is registered with the Drug Enforcement Administration (DEA) to handle controlled substances, such as opioids. The manufacturing process to synthesize the small molecule, including cGMP production, also aligns with the services provided by the company’s Durham facility.
Through this collaboration, MMRF now has the small molecule component required to optimize the bioconjugation stage of the synthetic vaccine’s overall manufacturing process. GMP production of the molecule and associated conjugate vaccine to support clinical development will follow shortly thereafter.
Source: Avista Pharma Solutions
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
